Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Charité coverage

This article was originally published in The Gray Sheet

Executive Summary

Cigna is the latest major payer to cover Johnson & Johnson/DePuy Spine's Charité artificial lumbar disc, the firm announces July 25. Cigna, which provides health insurance to 47 million people, joins Kaiser Permanente and Aetna, among others, who cover use of the device to treat degenerative disc disease. CMS and other payers' hesitance to cover the device, particularly due to lack of long-term follow-up data, has slowed acceptance of the procedure in the United States (1"The Gray Sheet" June 4, 2007, p. 5). DePuy says five-year Charité data is expected to be published this year...

You may also be interested in...

CMS Extends Non-Coverage Policy To All Artificial Lumbar Discs

CMS is proposing to extend its national non-coverage policy for Johnson & Johnson/DePuy's Charité to all current and future artificial lumbar discs

Interview: Arvelle Aims To Be Major Player In CNS

The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.

The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance

Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts